Advent Venture Raises $120 Million for First Life Sciences Fund

Nov. 24 (Bloomberg) -- Advent Venture Partners LLP, a
London-based investment firm, has raised $120 million for its
first life science fund.

The fund will invest in early- to mid-stage life science
companies in the U.K., Europe and U.S. and will be managed by
partners Shahzad Malik and Raj Parekh, Advent said in an e-mailed statement today.

Advent has invested in PowderMed, which was bought by
Pfizer Inc.; Thiakis, which was purchased by Wyeth, and
Respivert, which was bought by Johnson & Johnson.